This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
MabVax Therapeutics Holdings, Inc.
Drug Names(s): TLK286, TER286, canfosfamide HCL
Description: Telcyta, a glutathione analog, is activated by an enzyme – glutathione S-transferase – that is enriched in cancer cells. Once activated, the drug causes apoptosis (programmed cell death), leading to the killing of cancer cells. Direct triggering of apoptosis in cancer cells is a promising approach, enhancing natural processes that lead to tumor cell death.
Telik and MabVax
In May 2014, Telik and MabVax have entered into a definitive merger agreement. Under the terms of the merger agreement, MabVax will merge with a wholly-owned subsidiary of Telik in an all-stock transaction.
Pink Sheet Telik Telcyta vs. Iressa
Additional information available to subscribers only: